Valuation: Obalon Therapeutics Inc

Market Cap 14.74M 12.95M 11.93M 11.15M 20.92M 1.39B 21.3M 143M 55.43M 686M 55.35M 54.14M 2.38B P/E 2026 *
-2.99x
P/E 2027 * -2.31x
Enterprise Value 14.74M 12.95M 11.93M 11.15M 20.92M 1.39B 21.3M 143M 55.43M 686M 55.35M 54.14M 2.38B EV / Sales 2026 *
98.3x
EV / Sales 2027 * 59x
Free-Float
-
Yield 2026 *
-
Yield 2027 * -

Financials

2026 *2027 *
Net sales 150K 132K 121K 114K 213K 14.15M 217K 1.46M 564K 6.98M 563K 551K 24.25M 250K 220K 202K 189K 355K 23.59M 361K 2.43M 940K 11.63M 939K 918K 40.41M
Net income -4.89M -4.3M -3.96M -3.7M -6.94M -461M -7.07M -47.48M -18.39M -227M -18.36M -17.96M -790M -7.77M -6.82M -6.29M -5.88M -11.03M -733M -11.23M -75.44M -29.22M -361M -29.17M -28.54M -1.26B
Net Debt - -
Logo Obalon Therapeutics Inc
Obalon Therapeutics, Inc. is a commercial-stage medical device company focused on developing and commercializing medical devices to treat obese and overweight people by facilitating weight loss. The Company's product, Obalon balloon system, is a swallowable, gas-filled intragastric balloon designed to provide weight loss in obese patients. The Obalon balloon system is intended to be used as an adjunct to a moderate intensity diet and behavior modification program. All balloons must be removed six months after the first balloon is placed. The Obalon balloon system intends to provide patients and physicians with a reversible and repeatable weight loss solution in an outpatient setting, without altering patient anatomy or requiring surgery. The Company has received Premarket approval (PMA) for its Obalon balloon system based on the results of its United States pivotal clinical trial, referred to as the SMART trial.
Employees
-
Sector
-